These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 4526298)

  • 21. Review of recent studies of cellular proliferation in acute leukemia.
    Clarkson BD
    Natl Cancer Inst Monogr; 1969 May; 30():81-120. PubMed ID: 5260445
    [No Abstract]   [Full Text] [Related]  

  • 22. [Cytokinetic effect of cytosine arabinoside in clinical tests].
    Barlogie B; Büchner T; Asseburg U; Kamanabroo D
    Med Welt; 1974 Sep; 25(39):1532-4. PubMed ID: 4530133
    [No Abstract]   [Full Text] [Related]  

  • 23. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA; Morgenstern B; Capizzi RL
    Cancer Res; 1982 Jun; 42(6):2191-7. PubMed ID: 7074600
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo cellular kinetic and pharmacological studies of 1-beta-D-arabinofuranosylcytosine and 3-deazauridine chemotherapy for relapsing acute leukemia.
    Barlogie B; Plunkett W; Raber M; Latreille J; Keating M; McCredie K
    Cancer Res; 1981 Mar; 41(3):1227-35. PubMed ID: 7459863
    [No Abstract]   [Full Text] [Related]  

  • 25. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
    Lu C; Hassan HT
    Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells.
    Leclerc JM; Momparler RL
    Cancer Treat Rep; 1984 Sep; 68(9):1143-8. PubMed ID: 6592037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
    Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
    Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Self-renewal capacity of leukemic blast progenitor cells.
    Buick RN; Chang LJ; Messner HA; Curtis JE; McCulloch EA
    Cancer Res; 1981 Nov; 41(11 Pt 2):4849-52. PubMed ID: 6945908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K; Nayak R; Grant S
    Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Observation and care in high-dose cytarabine treatment of acute myelogenous leukemia].
    Xi YR; Tu YL; Zhao XH
    Zhonghua Hu Li Za Zhi; 1996 Nov; 31(11):653-5. PubMed ID: 9304928
    [No Abstract]   [Full Text] [Related]  

  • 31. Combination chemotherapy of acute leukaemia in adults. Comparison of two schedules.
    Scand J Haematol; 1974; 12(5):341-5. PubMed ID: 4527707
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacokinetics of 1-beta-D-arabinofuranosylcytosine in humans.
    Wan SH; Huffman DH; Azarnoff DL; Hoogstraten B; Larsen WE
    Cancer Res; 1974 Feb; 34(2):392-7. PubMed ID: 4521089
    [No Abstract]   [Full Text] [Related]  

  • 33. Terminal differentiation of the human promyelocytic leukemia cell line, HL-60, in the absence of cell proliferation.
    Ferrero D; Tarella C; Gallo E; Ruscetti FW; Breitman TR
    Cancer Res; 1982 Nov; 42(11):4421-6. PubMed ID: 6957259
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of primary acute myeloid leukemia: results of a prospective multicenter trial including high-dose cytarabine or stem cell transplantation as post-remission strategy.
    Brunet S; Esteve J; Berlanga J; Ribera JM; Bueno J; Martí JM; Bargay J; Guardia R; Juliá A; Granena A; Montserrat E; Sierra J;
    Haematologica; 2004 Aug; 89(8):940-9. PubMed ID: 15339677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of 1-beta-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function.
    Kufe DW; Munroe D; Herrick D; Egan E; Spriggs D
    Mol Pharmacol; 1984 Jul; 26(1):128-34. PubMed ID: 6431261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA.
    Major PP; Egan EM; Beardsley GP; Minden MD; Kufe DW
    Proc Natl Acad Sci U S A; 1981 May; 78(5):3235-9. PubMed ID: 6942429
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High-dose cytosine arabinoside: advances in clinical pharmacology and therapeutic results.
    Woodruff RK; Wiley JS
    Aust N Z J Med; 1983 Dec; 13(6):561-3. PubMed ID: 6586146
    [No Abstract]   [Full Text] [Related]  

  • 38. Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia.
    Liu J; Mi Y; Fu M; Yu W; Wang Y; Lin D; Bian S; Wang J
    Am J Hematol; 2009 Jul; 84(7):422-7. PubMed ID: 19484734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of-beta-D-arabinofuranosylcytosine on growth, viability, and DNA synthesis of mouse L-cells.
    Graham FL; Whitmore GF
    Cancer Res; 1970 Nov; 30(11):2627-35. PubMed ID: 5530557
    [No Abstract]   [Full Text] [Related]  

  • 40. [Efficacy and safety of induction chemotherapy consisting of anthracycline for 3 days and cytarabine for 7 days in elderly patients with acute myeloid leukemia].
    Kurahashi S; Iwasaki T; Suzuki H; Sawamoto A; Sugimoto T; Narimatsu H; Adachi T; Hayakawa F; Sugiura I
    Gan To Kagaku Ryoho; 2007 Oct; 34(10):1617-21. PubMed ID: 17940376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.